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Abstract
Background: Toxoplasma gondii is a widespread intracellular parasite, which infects most vertebrate animal hosts
and causes zoonotic infection in humans. Vaccine strategy remains a promising method for the prevention and
control of toxoplasmosis. T. gondii GRA4 protein has been identified as a potential candidate for vaccine
development. In our study, we evaluated the immune response induced by four different immunization vaccination
strategies encoding TgGRA4.
Methods: BALB/c mice were intramuscularly (i.m.) immunized four times according to specific immunization
schedules. Generally, mice in experimental groups were immunized with polypeptide, pGRA4, peptide/DNA, or
DNA/peptide, and mice in the control groups were injected with PBS or pEGFP. After immunization, the levels
of IgG antibodies and cytokine productions were determined by enzyme-linked immunosorbent assays (ELISA).
The survival time of mice was also evaluated after challenge infection with the highly virulent T. gondii
RH strain.
Results: The results showed that mice vaccinated with different immunization regimens (polypeptide, pGRA4,
peptide/DNA, or DNA/peptide) elicited specific humoral and cellular responses, with high levels of total IgG,
IgG2a isotype and gamma interferon (IFN-γ), which suggested a specific Th1 immunity was activated. After
lethal challenge, an increased survival time was observed in immunized mice (11.8 ± 4.8 days) compared to
the control groups injected with PBS or pEGFP (P < 0.05). Mice injected with PBS or pEGFP died within
8 days, and there was no significant difference in the protection level in two groups (P > 0.05).
Conclusions: These results demonstrated that this DNA prime and peptide boost immunization protocol
encoding the TgGRA4 can elicit the highest level of humoral and cellular immune responses compared to
other immunized groups, which is a promising approach to increase the efficacy of DNA immunization.
Background
Toxoplasma gondii is a widespread intracellular parasite
belonging to the phylum Apicomplexa, which infects
most vertebrate animal hosts and causes zoonotic infec-
tion in humans [1]. In general, an asymptomatic but
chronic infection is established in immunocompetent
individuals; However, in selected immunocompromised
human, and in particular those with human immuno-
deficiency virus (HIV) infection, T. gondii can result in
the extensive and fatal tissue damage [2]. The life cycle
of T. gondii consists of two phases: the sexual stage only
in felines and the asexual stage in human and other
intermediate hosts [3]. The asexual component com-
prises two distinct stages of growth: rapidly growing
‘tachyzoites’ and latent ‘bradyzoite’ tissue cysts [4]. Host
cell invasion and lysis by the actively dividing tachyzoites
are directly responsible for toxoplasmosis, which is
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particularly severe in immunocompromised individuals
and in the congenitally infected fetus [5,6].
Although drugs are the primary strategy for the treat-
ment of toxoplasmosis, they are poorly tolerated, have
severe side effects and drug-resistance, and cannot act
against chronic T. gondii infection [3]. It is known that
individual patients infected with T. gondii have serious
consequences and the disease burden of congenital toxo-
plasmosis on a population level is considerably high [7].
Thus, the development of an effective and safe vaccine
against T. gondii acute and chronic infection is an
important and urgent goal. So far, only a commercial
vaccine is deployed to control toxoplasma abortion in
sheep, which comprises live tachyzoites of the S48
‘incomplete’ strain of T. gondii [8]. In human, an effect-
ive vaccine could be valuable for preventing both fetal
infection and reactivation in immunocompromised indi-
viduals; In livestock such as sheep and goats, it could
prevent spontaneous abortion, decrease economic losses
and reduce the potential for a major epidemiologic
vector for human infection [9,10]. In general, proteins
or peptides and DNA vaccines are considered as the
third generation subunit vaccines, which are important
in preventing intracellar parasites infection [11]. DNA
vaccines encoding specific antigen can activate all path-
ways of immune response, with production of antibody,
Th1-dominated CD4+ T cells and CTLs (cytotoxic T-cell
responses), and provide protection against diseases that
require cell-mediated immunity such as intracellular
protozoan infections [12]. DNA vaccines against T. gondii
have been proved that they can induce antibody, specific
T-cell responses and protective immunity against acute
and chronic challenge in mice [13,14]. In contrast to DNA
vaccines, synthetic multiple antigen peptide (MAP) vac-
cines are an effective and new approach to deliver multiple
T-cell and B-cell epitopes as the constituents of a single
immunogen, which contains a high concentration of the
relevant antigen for inducing immune responses to prede-
fined epitopes [15]. Synthetic MAP vaccines have been
shown to elicit better cell-mediated immunity by focusing
the host immune response on epitopes known to play a
role in protective immunity [16,17]. Recently, several stud-
ies have demonstrated the power of synthetic polypeptides
vaccines in eliciting protective immunity to intracellular
parasites such as Plasmodium falciparum [18], Schis-
tosoma mansoni [19], T. gondii [17], and Paracoccidioides
brasiliensis [20].
Lots of studies indicate that the family of promising vac-
cine candidate antigens includes surface antigen (SAGs)
[21], dense granule proteins (GRAs) [22], rhoptry proteins
(ROPs) [23], and micronemal proteins (MICs) [24]. GRA
proteins, highly expressed by T. gondii, are involved in
parasite survival and virulence and are the major member
of the excreted secreted antigens (ESA) [25,26]. Among
the GRA proteins, GRA4 has been identified as the lead-
ing candidate for vaccine development [27]. In mice im-
munized with plasmids encoding for GRA4 antigen or the
recombinant GRA4 protein generated a Th1 type immune
response and provided partial protection against parasite
infection [28,29]. Concerning GRA4 peptides, amino acids
229-242 and 231-245 containing B and T-cell epitopes can
induce both humoral and cellular immune responses
following oral infection with T. gondii [30,31]. Multi-
epitope DNA vaccine expressing six antigen segments of
SAG1, GRA1 and GRA4 produced stronger humoral and
Th1-type cellular immune responses, which is a potential
strategy for the control of toxoplasmosis [32]. A multiple
antigenic peptide (MAP) vaccine including one B-cell and
two T-cell epitopes derived from T. gondii antigens
(SAG1, GRA4 and GRA1) could trigger stronger humoral
and cellular responses against T. gondii [17]. Therefore,
GRA4 is an attractive and promising vaccine candidate
against T. gondii and GRA4 231-245 peptide containing
B and T-cell determinants has been proved to be im-
munogenic, and was considered suitable alternative in
polypeptide vaccine design.
Furthermore, vaccination strategy is also a key factor in
influencing immunity, which is as important as vaccine
candidates [33]. One particularly promising approach is
the prime-boost strategy, which has been shown to gener-
ate high level of T-cell memory in animal models [34]. To
increase antibody production following DNA immuniza-
tions, prime-boost regimens have been shown to be an
effective approach to induce both humoral and cellular
immune responses [35,36]. The key strength of this strat-
egy is that greater levels of immunity are established by
heterologous prime-boost in which the antigen is applied
via different routes and immunization sites [34].
The aim of the present study is to investigate their
protective efficacy of different immunization regimens
(polypeptide, pGRA4, peptide/DNA, or DNA/peptide) in
mice against lethal T. gondii challenge. Our results dem-
onstrate that the DNA prime-peptide boost vaccination
regime can elicit the highest level of humoral and cellu-
lar immune responses, and is an effective strategy in
increasing efficacy of DNA immunization.
Methods
Mice and parasite
Specific-pathogen-free (SPF) grade female Kunming and
BALB/c mice (6-8 weeks old) were purchased from
Shandong University Laboratory Animal Centre (Jinan,
China). In this study, the T. gondii RH strain (Type I), a
highly virulent strain for mice, was used to challenge im-
munized BALB/c mice. Tachyzoites of the RH strain was
maintained in liquid nitrogen and recovered routinely by
intraperitoneal passage in Kunming mice in our labora-
tory according to the method previously described [37].
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Tachyzoites of T. gondii were harvested from the peri-
toneal fluid of Kunming mice that had been intraperito-
neally infected three days earlier. Soluble tachyzoite
antigen (STAg) was obtained from RH strain tachyzoites
as previously described [38]. Briefly, parasites obtained
from the peritoneal exudates were washed three times by
centrifugation, then suspended in sterile phosphate buff-
ered saline (PBS) and sonicated for three 10 min periods
at 60 w/s. The toxoplasma sonicate was centrifuged at
2100 × g for 15 min. The supernatant, containing soluble
tachyzoite antigens (STAg), was harvested and stored
at -80°C until further use.
Construction of the eukaryotic expression plasmid
The total genomic DNA of T. gondii RH strain was
extracted from purified tachyzoites using a commercial
kit (QIAGEN, Germany) and used as a template DNA
for the polymerase chain reaction (PCR). The coding
sequence of the T. gondii GRA4 gene [GenBank:
AAA30142.1] was amplified from the T. gondii genomic
DNA, with a pair of specific synthetic primers (forward
primer: 5′- CGGGGTACCATGCAGGGCACTTGGTT
TTC -3′, reverse primer: 5′- CGCGGGATCCTCACTC
TTTGCGCATTCTTT -3′), in which KpnI and BamHI
restriction sites were introduced. The PCR conditions
were as follows: pre-denaturation at 94°C for 5 min; de-
naturation at 94°C for 30 s, annealing at 65°C for 30 s
and extension at 72°C for 1 min, followed by 30 cycles;
final extension at 72°C for 10 min. The sequence of
amplified GRA4 DNA fragment was verified by double-
stranded sequencing. The GRA4 DNA fragment was
subcloned into the eukaryotic expression vector pEGFP-
C1 (Clontech, USA) to form the plasmid pEGFP-GRA4
using KpnI and BamHI restriction sites. The recombin-
ant plasmids were then transformed into Escherichia coli
DH5α. Positive recombinant plasmids were verified using
PCR, double restriction enzyme digestion and double-
stranded sequencing. The plasmids were purified using an
endotoxin-free plasmid purification kit following themanu-
facturer’s instructions, and stored at -20°C until use. The
concentration of pGRA4 was determined by spectropho-
tometer at OD 260 andOD 280, and the ratios were 1.8-2.0.
Design and synthesis of peptide
Peptide constructs were synthesized, purified, and identi-
fied as described previously [17,39]. Briefly, MAP vaccine
of GRA4 was designed based on the published peptide
sequences containing T-cell epitopes and B-cell epitopes
[17,40]. In this study, peptide 231-245 (STEDSGLT-
GVKDSSS) was selected and polypeptides were synthe-
sized by Xi’an Bio-scientific Co., Ltd with the Solid-Phase
Peptide Synthesizer by adopting four-branched peptide
design. The purity of the peptide was confirmed by ana-
lytic HPLC.
pEGFP-GRA4 plasmid expression in vitro
HEK293T cells were maintained in our laboratory and
routinely cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with penicillin (100 IU/ml),
streptomycin (100 mg/ml) and 10% fetal bovine serum
(FBS) at 37°C with 5% CO2. The in vitro transfection assay
was performed as previously described [41]. Briefly, before
transfection, 2 × 104 HEK293T cells were seeded in a 6-
well plate. The recombinant pGRA4 plasmid (2 μg/well)
was transfected into cells using the Fugene HD transfection
reagent as instructed by the manufacturer. pEGFP plasmid-
transfected cells and untransfected cells were used as the
controls. Plates were incubated for 48 h at 37°C in 5% CO2,
95% humidity. The plasmid pGRA4 expression in the cells
was detected by western blotting analysis.
Protein productions from HEK293T cells were collected
on ice with RIPA Lyses Buffer (50 mM Tris pH 7.4,
150 mM NaCl, 1% Triton X-100, 1% Sodium deoxycholate,
0.1% SDS) containing 1 mM protease inhibitor PMSF
(phenylmethanesulfonyl fluoride). The expression of plas-
mid pGRA4 in HEK cells were demonstrated by western
blotting with anti-T. gondii polyclonal antibody (Goat) and
a HRP (horseradish peroxides)-labeled rabbit anti-goat IgG
antibody (Sigma, USA) as a secondary antibody. The
conjugated substrate was visualized with ECL chemilumi-
nescence’s reagents as described previously [13], and west-
ern blot marker (CWBIO, China) was used as molecular
mass standards.
Immunization and challenge
Six groups of BALB/c mice (n = 12 each) were individu-
ally immunized intramuscularly (i.m.) four times at two
weeks interval. The specific immunization schedules and
methods for mice are shown in Table 1. Blood samples
from each group were collected from the tail vein at the
end of each interval, four times in total and sera were
separated and stored at -20°C until analyzed for specific
antibodies. Two weeks after the last immunization, three
mice per group were sacrificed and splenocytes were
harvested under aseptic conditions for cytokine assays,
and thereafter the remaining mice in all groups were
intraperitoneally (i.p.) challenged with 1 × 103 T. gondii
RH strain tachyzoites suspended in 100 μl phosphate-
buffered saline (PBS) to observe the percentage of mice
surviving.
Determination of antibodies by ELISA
IgG, IgG1 and IgG2a antibodies in sera samples were
determined using an indirect ELISA assay according to
the manufacture’s instructions (R&D Systems, USA). In
brief, the 96-well microtiter plates were coated over
night at 4°C with STAg in 50 mM carbonate buffer
(pH 9.6). On the second day, the plates were washed
three times with PBS containing 0.05% Tween20 (PBST)
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and then blocked with 1% Bovine Serum Albumin (BSA)
for 1 h at 37°C. Thereafter, the wells were washed and
incubated with mice sera diluted in PBS for 1 h at 37°C.
HRP-conjugated goat anti-mouse IgG, IgG1 or IgG2a di-
luted in PBS (Sigma, USA) were used as the secondary
antibody and added to the wells for determination of
antibody levels and isotype analysis, respectively. Finally,
immune complexes were visualized by incubating with
orthophenylene diamine (Sigma, USA) and 0.15% H2O2
for 30 min. The reaction was stopped by adding 2 M
H2SO4, and the absorbance was measured at 490 nm
with an ELISA reader (BiotekELx800, USA). All samples
were run in triplicate.
Cytokine assay
To assay for the levels of cytokine productions, spleens
were aseptically removed from three mice per group two
weeks after the last injection and splenocytes were
obtained as described above and cultured in 96-well mi-
crotiter plates. Cell-free supernatants were harvested
from microtiter plates and assayed for cytokine levels.
The assays were performed for interleukin-4 (IL-4) activ-
ity at 24 h, interleukin-10 (IL-10) activity at 72 h, and
gamma interferon (IFN-γ) activity at 96 h using a com-
mercial ELISA kit ( R&D Systems, USA) following the
manufacturer’s recommendations. All samples were
performed in triplicate.
Statistical analysis
Statistical analysis and graphics were performed using
SPSS software. All data, including antibody levels and
cytokine productions, were compared between the dif-
ferent groups by one-way ANOVA. Survival time among
all the groups was compared using the Kaplan-Meier
method. The results in comparisons were considered
different if P < 0.05.
Ethics statement
This study was approved by the Institutional Animal
Care and Use Committee of Shandong University under
Contract 2011-0015, and the animals were kept and the
experiments were performed in accordance with com-
mittee’s criteria for the care and use of laboratory ani-
mals. All mice were maintained in specific pathogen-free
conditions, and all efforts were made to minimize suffer-
ing. Humane endpoints to reduce pain or distress in
mice were used via euthanasia. Mice were monitored
daily for signs of toxoplasmosis, which included difficul-
ties with their food and water intake, lethargy, or severe
ascites. Mice with above signs were sacrificed immedi-
ately using CO2 gas. Generally, mice were placed in a
chamber and CO2 was administered at a concentration
of 60% to 70% over a 5-minute exposure time, after
which the cervical dislocation method was sometimes
used to ensure that effective euthanasia had occurred.
Results
Expression of plasmid pGRA4 in HEK293T cell
Forty-eight hours after HEK cells were transfected
with pGRA4 or empty plasmid pEGFP, specific green
fluorescence was observed under a fluorescence mi-
croscope, whereas there was no signal in the un-
transfected cells (Figure 1A, B & C). In the western
blotting analysis (Figure 1D), a specific protein band
(about 70 kDa) was detected in cells transfected with
pGRA4, but not in cells transfected with empty plas-
mid or untransfected cells. The fusion protein of
about 70 kDa consists of the target protein GRA4
(about 40 kDa) and green fluorescent protein (about
30 kDa). These results indicated that the recombinant
plasmid was successfully constructed and expressed
in vitro and recombinant TgGRA4 protein possessed
immunological activity.
Evaluation of the antibody responses by ELISA
To determine the specific antibody titers in all vaccin-
ation protocols, the levels of T. gondii-specific IgG and
IgG subclasses in the sera of mice were assayed by
ELISA with STAg as coating antigens. As shown in
Figure 2, significantly high levels of IgG antibody
appeared following injection of polypeptide, pGRA4,
peptide/DNA, and DNA/peptide, as compared to the
control groups (P < 0.05). As expected, mice injected
with PBS and pEGFP did not generate specific antibody
response. In all vaccination protocols, the DNA prime-
peptide boost regimen leads to remarkable increase in
specific IgG antibody production compared to other im-
munized groups (polypeptide, pGRA4, or peptide/DNA)
(P < 0.05). However, there was no statistical difference in
mice vaccinated with polypeptide, pGRA4, or peptide/
DNA (P > 0.05).
Table 1 Specific immunization regimes of BALB/c mice
Groupsa Immunization time
1st 2nd 3rd 4th
PBS 100 μl 100 μl 100 μl 100 μl
pEGFPb 100 μg 100 μg 100 μg 100 μg
pGRA4c 100 μg 100 μg 100 μg 100 μg

















aAll mice of six groups were intramuscularly injected four times at two
week interval.
bEach mouse, 100 μg pEGFP resuspended in 100 μl PBS.
cEach mouse, 100 μg pGRA4 resuspended in 100 μl PBS.
dEach mouse, 100 μg peptide resuspended in 100 μl PBS.
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In order to determine whether a Th1 and/or Th2 re-
sponse was elicited in the immunized mice, we measured
by ELISA the specific IgG1 and IgG2a subclasses at the
second week after the final immunization. As depicted in
Figure 3, an IgG2a predominant production over IgG1
was detected in the sera of vaccinated mice. Apparently,
in mice immunized with DNA/peptide, the level of IgG2a
was significantly increased (P < 0.05), compared with mice
immunized with peptide/DNA (P < 0.05). This profile of
IgG2a over IgG1 suggested that the heterologous DNA
Figure 1 Fluorescence microscopy images of HEK293T cells and western blotting analysis. (A) HEK293 cells transfected with empty vector
pEGFP-C1. (B) HEK293 cells transfected with pGRA4. (C) untransfected HEK cells. (D) protein marker (lane M), pGRA4-transfected cells (lane 1),
pEGFP-transfected cells (lane 2), untransfected cells (lane 3).
Figure 2 Levels of specific IgG antibodies in BALB/c mice. Sera samples of mice were collected from the tail vein at the end of each interval,
four times in total and analyzed by ELISA. Results are shown as mean ± SD and statistically significant differences (P < 0.05) are indicated by (*) as
compared to control groups.
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prime-peptide boost strategy elicited a specific humoral
response, and with a Th1-type immune response.
Cytokine production by spleen cells
Culture supernatants of splenocytes from individual
mice were harvested two weeks after the final vaccin-
ation and were assessed for the production of IFN-γ,
IL-4 and IL-10 activities at different times. As shown in
Figure 4, large amounts of IFN-γ were detected in the
restimulated splenocyte cultures of all the treatment
mice as compared to the control groups (P < 0.05). Mice
vaccinated with DNA/peptide generated higher level of
IFN-γ compared with pGRA4 or polypeptide alone
(P < 0.05). In the meanwhile, no significant difference
was observed in IL-4 and IL-10 levels between these
groups (P > 0.05). Generally, both Th1 cytokines (IFN-γ
and IL-2) and Th2 cytokines (IL-4 and IL-10) are the
major parameters to define whether a Th1 and/or Th2 im-
mune response was induced [22]. The high level of IFN-γ
and low level of IL-4 and IL-10 suggested that the cellular
Figure 3 Determination of IgG subclass IgG1 and IgG2a in the sera of BALB/c mice. Sera were taken from mice in all groups two weeks
after the last immunization and was analyzed by ELISA. Statistically significant differences (P < 0.05) are indicated by an asterisk (*) as compared to
control groups.
Figure 4 Cytokine productions by spleenocyte cultures from mice. Splenocytes were collected from three mice per group two weeks after
the final immunization to detect the level of IFN-γ, IL-4 and IL-10. Data are expressed as mean ± SD. Statistically significant differences (P < 0.05)
are indicated by (*) compared with negative control.
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immune response induced by the heterologous DNA
prime-peptide boost strategy was an enhanced, Th1-
biased immunity, further confirming the results of the IgG
subclass as shown above.
Evaluation of the survival time in BALB/c mice
To evaluate the protective effect of different vaccination
protocols against T. gondii infection, mice in all groups
were intraperitoneally challenged with 1 × 103 tachyzoites
of the virulent RH strain two weeks after last
immunization. Survival curves of those different groups of
mice are shown in Figure 5. An increased survival time
was observed in immunized mice (11.8 ± 4.8 days)
compared to the control groups injected with PBS or
pEGFP (P < 0.05). Mice injected with PBS or pEGFP died
within 8 days, and there was no significant difference in
the protection level in two groups (P > 0.05). Mice immu-
nized with DNA /peptide provide significantly higher
protection, with remarkable increase in survival time
(16.5 ± 5.4 days), and 40% survival rate was achieved after
a lethal challenge, as compare with pGRA4 (11.5 ±
4.1 days), polypeptide (9.0 ± 3.0 days), or peptide /DNA
(10.3 ± 3.2 days) (P < 0.05). These results demonstrated
DNA prime-peptide boost protocol is an effective
approach to produce protection against T. gondii acute
infection.
Discussion
In the present study, we have compared the protective
efficacy of different immunization strategies in BALB/c
mice. Our results suggested that all the vaccination regi-
mens can trigger a significantly higher level of humoral
and cellular immune responses than the control groups
injected with PBS or pEGFP. Especially, the regime with
DNA vaccine priming followed by peptide boosting elic-
ited significantly high levels of IgG, IgG2a and IFN-γ
secretion, which is an effective approach to provide pro-
tection against lethal T. gondii infection.
Immunotherapy may be one of the most promising
approaches to prevent the infection of T. gondii. DNA
vaccines encoding TgGRA4 often induce a specific Th1-
polarized immune response, but DNA vaccine is often
poorly immunogenic, and cannot produce enough pro-
tection against T. gondii challenge [28,42]. Heterologous
prime-boost strategies have emerged as a powerful
vaccination approach for inducing very strong cellular
immunity, which involve the administration of two dif-
ferent vaccines expressing the same antigen, given sev-
eral weeks apart [43]. The mechanism of prime-boost
regimen is that the first immunization initiates the prim-
ing of the immune response and subsequent immuniza-
tions trigger further expansion of antigen specific cells
and selection of cells with high antigen avidity to boost
the specific responses [11]. Recently, several reports have
demonstrated the efficacy of heterologous prime-boost
vaccination strategies in generating protective immune
response to a variety of pathogens, including malaria
[44], Leishmania [45], and hepatitis C virus [46]. To
overcome a significantly lower antibody titer following
DNA immunization, prime-boost strategies have been
used to increase immune responses to a number of
DNA vaccines [47]. Concerning GRA4, DNA prime and
a vaccinia virus boost immunization regimen has been
evidenced and can induce effective immune responses
[35]. Priming with DNA and boosting with polypeptide
is another new and promising approach. In our present
Figure 5 Survival curves of BALB/c mice in all groups after T. gondii acute challenge. Each mouse was challenged intraperitoneally with
1 × 103 T. gondii RH strain tachyzoites at two weeks after the last immunization. Survival times were monitored daily after the challenge. Each
group was composed of nine mice.
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study, DNA prime-peptide boost immunization regimen
encoding TgGRA4 has been proved to be very effective
for eliciting humoral and cellular responses in BALB/c
mice.
Humoral and cellular immunity play an important role
in host resistance against T. gondii. Primary infection
with T. gondii results in a strong and persistent Th1-
type immune response, defined by the high level of IgG
antibody response and large amounts of cytokines,
which are essential for the control of infection [48,49].
Their findings have suggested that a good immunization
protocol should be able to direct the T-helper cells to-
ward a Th1 rather than a Th2-type response [50]. Regard
to the roles of humoral immunity, specific IgG anti-
bodies play a protective role in controlling T. gondii
chronic infection in collaboration with macrophages and
preventing reactivation because IgG antibodies can
inhibit the attachment of the parasite to the host cell
receptors [51]. In this study, only the immunized mice
had remarkable levels of serum antigen-specific IgG
antibodies, with a high ratio of IgG2a to IgG1 antibody
titers. A significant higher level of IgG antibodies re-
sponses was detected in mice immunized with DNA/
peptide as compared with other groups immunized with
peptide, pGRA4 or peptide/DNA (P < 0.05). These re-
sults indicated that specific Th1 cells were mainly acti-
vated, which was further confirmed by analysis of the
cytokine productions.
To further characterize the polarization of the immune
response, the levels of cytokine productions (IFN-γ, IL-4
and IL-10) from spleen cells of mice were evaluated.
Generally, cytokines play an important role in host
resistance against T. gondii. IFN-γ-dependent cell-
mediated immunity was important in early infection and
control the replication of the protozoan [52]. Meanwhile,
IFN-γ is of primary importance in restricting the growth
of T. gondii in the acute phase of the infection and
preventing reactivation of parasites from dormant cysts
[53]. Furthermore, a previous study suggested that IFN-γ
correlates with the differentiation of Th1 cells and IL-4
induces the development of Th2 cells [54]. Therefore,
IFN-γ can be considered as a marker for protective im-
munity against T. gondii. Meanwhile, studies suggested
the level of Th2-associated cytokines (IL-4 and IL-10)
produced in T. gondii infection play an important role
in immune response. IL-4 appear relatively late after
infection, which perhaps prevents the host from suc-
cumbing to early Th1-polarized hyperactive immune
response that can be detrimental to the host, and high
level of IL-4 was known to antagonize the production of
IFN-γ [55,56]. Under our experimental conditions, high
level of IFN-γ production was induced in the experimental
mice as compared to the controls, whereas the produc-
tions of IL-4 and IL-10 were maintained at the same levels
and no significant difference was observed among all the
groups. It is obvious that the level of IFN-γ were signifi-
cantly higher than those of IL-4 and IL-10 especially in
DNA/peptide regimen, which suggested the findings are
typical of Th1-polarized signal, since the presence of IL-4
is a potent stimulus for Th2 differentiation. Therefore,
these findings indicated specific Th1-type immune re-
sponse was activated in response to TgGRA4, which are
consistent with previous studies [17,28].
The main purpose of vaccination is to generate
protective immune response against the infection of
T. gondii and prolong the survival time of mice. In this
study, 1 × 103 RH tachyzoites was used to challenge
immunized BALB/c mice. The RH strain of T. gondii is
highly virulent in mice and no previous vaccines have
been reported to provide entirely protect against in-
traperitoneal challenge with T. gondii [38,57]. In contrast
to the non-immunized mice, a significantly prolonged
survival time was obtained in all immunized mice. In
addition, the survival rate of the DNA/peptide group
reached to 40%, whereas mice in other groups died
within 20 days. In all vaccination strategies, DNA/pep-
tide produces an effective and significant degree of pro-
tection, and the effective and strong immunity acquired
in the vaccination is capable of protecting the mice from
T. gondii lethal acute challenge infection. Although the
immunizations did not provide complete protection
against acute challenge with T. gondii, the survival time
of mice is longer and the survival rate was significantly
increased than control groups. In this study, we mainly
analyze a Th1-biased response to evaluate the efficiency
of vaccine, which is the major limitation of our current
study design. The immune response elicited by vaccine
in mice was complex, and it is not sufficient to merely
analyze a Th1-biased response. In the future study,
evaluating the efficiency of vaccine from different
aspects could be a new and promising strategy. In
addition, many factors, such as T. gondii strain, the
dose of inoculum, the inoculation route, and the
mouse strain, might hinder an efficient evaluation of
T. gondii vaccines [58]. It is known that intraperi-
toneal infection with tachyzoites is an unnatural route
though it can easily be performed. Thus, in some
immunization studies, oral challenge, the natural
route of infection, were made with cystogenic strains
[59]. Therefore, in our study, many parameters might
hinder the effective evaluation of protective immunity.
The current study is the lack of a full and systematic
evaluation of the immune response generated by dif-
ferent experimental parameters. In further studies,
considering different aspects and optimizing challenge
route could achieve more encouraging results and
effectively evaluate the immune response elicited by
T. gondii vaccine.
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Conclusions
In the present study, we have demonstrated that TgGRA4
can induce significant humoral and cellular Th1 immune
responses using a heterologous prime-boost vaccination
strategy. The results suggested DNA prime-peptide boost
vaccination elicited stronger humoral and cellular immune
responses against T. gondii as well as increased the sur-
vival rate significantly compared with the controls. There-
fore, this DNA prime-peptide boost immunization regime
based on GRA4 may be an important approach to prevent
T. gondii infection, particularly with respect to generating
an efficient protective immune response.
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